Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124025 | 0.88 | MEN1 (0.70) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL6436608 | 0.88 | PYGL (0.64) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL7122274 | 0.87 | PYGL (0.56) | MEN1KMT2AMAPTALDH1A1NPC1 | |
| SCHEMBL7117003 | 0.85 | MEN1 (0.65) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL2825277 | 0.85 | MEN1 (0.74) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL6431225 | 0.82 | PYGL (0.82) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL2828102 | 0.81 | SETD7 (0.71) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL6430923 | 0.80 | PYGL (0.82) | MEN1KMT2AHTTMAPTPYGL | |
| SCHEMBL6432282 | 0.80 | PYGL (0.84) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL7118351 | 0.78 | PYGL (0.54) | MEN1KMT2AHTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | KRISTIANSEN MARIT (DK) | 2003-10-02 | — | — | US | disclosed |
| US-6590118-B1 | Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) | NOVO NORDISK A/S (DK) | 2003-07-08 | — | — | US | disclosed |
| EP-1220832-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001023347-A1 | NOVEL AROMATIC COMPOUNDS | NOVO NORDISK A/S (DK) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186944-A1 | Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics | PYGL, GYS2, PYGM | MEN1 2301/4885KMT2A 971/4885HTT 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.